Lorlatinib Versus Crizotinib in Patients With Advanced <i>ALK</i> -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study

Solomon, Benjamin; Liu, Geoffrey; Felip, Enriqueta; Mok, Tony; A. Soo, Ross; Mazières, Julien; T. Shaw, Alice; de Marinis, Filippo; Goto, Yasushi; Wu, Yi‐Long; Kim, Dong‐Wan; Martini, Jean-François; Messina, Rossella; Paolini, Jolanda; Polli, Anna; Thomaidou, Despina; Toffalorio, Francesca; M. Bauer, Todd

doi:10.1200/jco.24.00581

Public

Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study

Published in Journal of Clinical Oncology • May 31, 2024

Authors:

Benjamin Solomon

Geoffrey Liu

Enriqueta Felip

Abstract

PURPOSE Lorlatinib improved progression-free survival (PFS) and intracranial activity versus crizotinib in patients with previously untreated, advanced, ALK -positive non–small cell lung cancer (NSCLC) in the phase III CROWN study. Here, we report long-term outcomes from CROWN after 5 years of follo...

Subject

Crizotinib

Medicine

Lung cancer

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!